Clinical Efficacy of Transurethral Resection of the Prostate Combined with Oral Anticholinergics or Botulinum Toxin - A Injection to Treat Benign Prostatic Hyperplasia with Overactive Bladder: A Case-Control Study

Farzad Allameh, Abbas Basiri, Mohammadreza Razzaghi, Amir Reza Abedi, Morteza Fallah-Karkan, Saleh Ghiasy, Seyyed Mohammad Hosseininia, Saeed Montazeri, Farzad Allameh, Abbas Basiri, Mohammadreza Razzaghi, Amir Reza Abedi, Morteza Fallah-Karkan, Saleh Ghiasy, Seyyed Mohammad Hosseininia, Saeed Montazeri

Abstract

Introduction: Recent investigations showed that anticholinergic drugs could use for the management of storage symptoms after transurethral resection of the prostate (TURP). The use of intravesical botulinum toxin-A (BTX-A) for the management of overactive bladder is rapidly increasing. In this research, we assess the efficacy of BTX-A vs solifenacin in men suffering from bladder outlet obstruction-over active bladder (BOO-OAB) managed with TURP.

Methods: In this case-control study, 50 men with BOO-OAB randomized into two groups. The control group (A) underwent TURP and subsequently managed by solifenacin 5 mg daily, and the case group (B) underwent TURP and BTX-A injection in the bladder wall in the same session. Treatment success was the primary outcome and defined as post-injection improvement in the storage score of the International Prostate Symptom Score (IPSS) from baseline.

Results: The IPSS, post-void residual volume, frequency, incomplete emptying, nocturia and urgency subscores considerably ameliorated after 12 weeks and 36 weeks for both groups, but it was more significant in the case arm. The quality of life (QoL) scores significantly improved after the treatments in both groups. Intervention group showed significant reductions regarding urgency incontinence compared with the solifenacin group at 12th and 36th weeks.

Conclusion: BTX-A is an effective and well-tolerated treatment in patients with benign prostatic hyperplasia (BPH) who are candidates of TURP and simultaneously suffer from OAB symptoms.

Keywords: TURP; anticholinergic drug; benign prostatic hyperplasia; botulinum toxin-A; over active bladder; solifenacin.

Conflict of interest statement

The authors have no conflicts of interest to declare.

© 2020 Allameh et al.

References

    1. Elterman DS, Barkin J, Kaplan SA. Optimizing the management of benign prostatic hyperplasia. Ther Adv Urol. 2012;4(2):77–83. doi:10.1177/1756287212437361
    1. Karami H, Hassanzadeh-Hadad A, Fallah-Karkan M. Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J. 2016;13(6):2920–2926.
    1. Oelke M, Baard J, Wijkstra H, Jean J, Jonas U, Höfner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54(2):419–426. doi:10.1016/j.eururo.2008.02.017
    1. Razzaghi MR, Karkan MF, Ghiasy S, Javanmard B. Laser application in Iran urology: a narrative review. J Lasers Med Sci. 2018;9(1):1. doi:10.15171/jlms.2018.01
    1. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319–2328. doi:10.1001/jama.296.19.2319
    1. Greenland JE, Brading AF. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol. 2001;165(1):245–248. doi:10.1097/00005392-200101000-00072
    1. Abrams P, Kaplan S, Gans HJDK, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3):999–1004. doi:10.1016/S0022-5347(05)00483-0
    1. Seki N, Kai N, Seguchi H, Takei M, Yamaguchi A, Naito S. Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology. 2006;67(2):306–310. doi:10.1016/j.urology.2005.08.015
    1. Machino R, Kakizaki H, Ameda K, et al. Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol Urodyn. 2002;21(5):444–449. doi:10.1002/nau.10057
    1. Antunes AA, Srougi M, Coelho RF, de Campos Freire G. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Nat Rev Urol. 2007;4(3):155.
    1. Gormley E, Griffiths D, McCracken P, Harrison G, McPhee M. Effect of transurethral resection of the prostate on detrusor instability and urge incontinence in elderly males. Neurourol Urodyn. 1993;12(5):445–453. doi:10.1002/nau.1930120502
    1. Seki N, Yuki K, Takei M, Yamaguchi A, Naito S. Analysis of the prognostic factors for overactive bladder symptoms following surgical treatment in patients with benign prostatic obstruction. Neurourol Urodyn. 2009;28(3):197–201. doi:10.1002/nau.20619
    1. Thomas AW, Cannon A, Bartlett E, Ellis-jones J, Abrams P. The long term urodynamic follow-up of turp. J Urol. 1999;161(4):257. doi:10.1097/00005392-199904020-00030
    1. de Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol. 2003;169(2):535–539. doi:10.1016/S0022-5347(05)63949-3
    1. Dmochowski R. Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? Curr Urol Rep. 2006;7(6):462–467. doi:10.1007/s11934-006-0055-4
    1. Blake‐James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta‐analysis. BJU Int. 2007;99(1):85–96. doi:10.1111/j.1464-410X.2006.06574.x
    1. Crawford ED, Hirst K, Kusek JW, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011;186(3):965–970. doi:10.1016/j.juro.2011.04.062
    1. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011;12.
    1. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53(2):275–287. doi:10.1016/j.eururo.2007.10.013
    1. Eckhardt MD, Van Venrooij GE, Van Melick HH, Boon TA. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. J Urol. 2001;166(2):563–568. doi:10.1016/S0022-5347(05)65985-X
    1. Yokoyama T, Uematsu K, Watanabe T, et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol. 2009;43(4):307–314. doi:10.1080/00365590902836740
    1. Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol. 2007;51(1):57–66. doi:10.1016/j.eururo.2006.07.050
    1. Cumming J, Chisholm G. Changes in detrusor innervation with relief of outflow tract obstruction. Br J Urol. 1992;69(1):7–11. doi:10.1111/j.1464-410X.1992.tb15448.x
    1. Chapple C, Smith D. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol. 1994;73(2):117–123. doi:10.1111/j.1464-410X.1994.tb07477.x
    1. Nitti VW, Adler H, Combs AJ. The role of urodynamics in the evaluation of voiding dysfunction in men after cerebrovascular accident. J Urol. 1996;155(1):263–266. doi:10.1016/S0022-5347(01)66614-X
    1. Housami F, Abrams P. Persistent detrusor overactivity after transurethral resection of the prostate. Curr Urol Rep. 2008;9(4):284–290. doi:10.1007/s11934-008-0050-z
    1. Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182(4):1453–1457. doi:10.1016/j.juro.2009.06.023
    1. Reitz A, Stöhrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45(4):510–515. doi:10.1016/j.eururo.2003.12.004
    1. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996;155(3):1023–1029. doi:10.1016/S0022-5347(01)66376-6
    1. Cruz F, Silva C. Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update. Curr Opin Urol. 2004;14(6):329–334. doi:10.1097/00042307-200411000-00006
    1. Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012;61(4):834–839. doi:10.1016/j.eururo.2011.12.011
    1. Smith CP, Franks ME, McNeil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol. 2003;169(5):1896–1900. doi:10.1097/01.ju.0000049202.56189.54
    1. Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9):665. doi:10.1056/NEJM200003023420918
    1. Schurch B, Stöhrer M, Kramer G, Schmid D, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3):692–697. doi:10.1016/S0022-5347(05)67283-7
    1. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41(4):335–340. doi:10.1080/00365590601068835
    1. Sahai A, Khan MS, Dasgupta P; Group GBS. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double blind, and placebo controlled trial. J Urol. 2007;177(6):2231–2236. doi:10.1016/j.juro.2007.01.130

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir